JPM26: Amgen touts MariTide’s weight loss, T2D potential off Phase II data
Amgen is hoping to gain a slice of the obesity market with MariTide, which it claims has a differentiated profile to other approved incretin therapies.
14 January 2026
14 January 2026
Amgen is hoping to gain a slice of the obesity market with MariTide, which it claims has a differentiated profile to other approved incretin therapies.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.